Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer.The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc.
IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS).Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains.
Geron is headquartered in Menlo Park, California, the US.
Geron Corp (GERN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
250 pages •
By Future Market Insight Global & Consulting Pvt Ltd
• Jun 2021
A recent market study published on the cow colostrum market offers a global industry analysis for 2016-2020 & an opportunity assessment for 2021–2031. The study offers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical and current growth parameters of the cow colostrum market,...
The thermal pallet covers market was valued at US$ 4,599.65 million in 2021 and is projected to reach US$ 10,469.73 million by 2028; it is expected to grow at a CAGR of 12.5% from 2021 to 2028. Thermal pallet covers safeguard temperature-sensitive goods from the effects of harsh weather and decrease the risk of excursions.The heat transmission...
Global Big Pharma Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides...
Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter Specialty Pharmaceutical partnering deals. This report provides details of the latest Specialty Pharmaceutical agreements announced in the life sciences since...
Retinoic Acid Receptor Gamma - Drugs In Development, 2021 Summary Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report...
Heparanase - Drugs In Development, 2021 Summary Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 184.108.40.206) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report...
Glucose Dependent Insulinotropic Receptor - Drugs In Development, 2021 Summary Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed...
Nociceptin Receptor - Drugs In Development, 2021 Summary According to the recently published report ’Nociceptin Receptor - Drugs In Development, 2021’; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 14 molecules. Out...
The market size of microcapsule is estimated at USD 8.4 billion in 2021 and is projected to reach USD 13.4 billion by 2026, at a CAGR of 9.8% from 2021 to 2026. The microcapsule market is on course for intense growth across different end-user industry verticals such as pharmaceuticals & healthcare, food, household & personal care, textiles,...
Health Insurance Claims
Household Consumption Expenditure
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.